Investment Rating - The report provides a positive outlook for the pharmaceutical and biotechnology sector, indicating a strong performance compared to the broader market indices [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.27%, outperforming the Wind All A index (0.72%) and the CSI 300 index (1.12%) [3][8]. - Key sub-sectors such as raw materials (3.79%), in vitro diagnostics (2.25%), and vaccines (1.98%) showed significant gains, while offline pharmacies (-1.24%) and blood products (-0.03%) experienced declines [3][9]. - The report highlights the competitive advantage of tirzepatide over semaglutide in weight loss efficacy, with tirzepatide achieving a 1.47 times greater relative weight reduction and a 64.6% participant rate achieving ≥15% weight loss compared to 40.1% for semaglutide [3][12]. - COVID-19 is entering a phase of periodic outbreaks, with increasing infection rates reported in various regions, prompting recommendations for booster vaccinations among older populations [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from May 12 to May 16 showed a 1.27% increase, with raw materials leading the gains at 3.79% [8]. - Notable individual stock movements included a significant rise in COVID-19 related stocks like Tuoxin Pharmaceutical, which surged by 45% [11]. Industry News and Key Company Announcements - Recent monitoring data from health authorities in Hong Kong and Singapore indicate a rise in COVID-19 cases, suggesting a potential peak in infections soon [11][13]. - Eli Lilly's tirzepatide clinical trial results demonstrate its superiority over Novo Nordisk's semaglutide in weight loss, indicating a promising market opportunity for obesity treatments [12][13]. - Several companies, including North Sea Kangcheng and Hengrui, have made significant announcements regarding new drug approvals and clinical trials, reflecting ongoing innovation in the sector [13][14].

Group 1 - The monitoring report from the Chinese CDC indicates an upward trend in the COVID-19 positive rate in April, with southern provinces showing higher rates than northern ones [1] - In Hong Kong, the COVID-19 positive rate increased from 1.71% to 8.21% over four weeks, indicating a rising trend in the region [1] - Taiwan reported a significant increase in emergency visits related to COVID-19, with a 66% rise in cases and additional severe cases and deaths [1] Group 2 - The Chinese CDC reported an increase in the COVID-19 positive rate among flu-like cases in emergency departments, rising from 7.5% to 16.2% [2] - Among hospitalized severe acute respiratory infection cases, the COVID-19 positive rate increased from 3.3% to 6.3% during the monitoring period [2] - The new coronavirus has surpassed rhinovirus as the leading cause of emergency visits for flu-like cases in the specified three-week period [2] Group 3 - Relevant pharmaceutical companies in the Hong Kong stock market include Shandong Xinhua Pharmaceutical (00719), Jinhongzi (06896), Sanofi (01530), and Dongyangguang Changjiang Pharmaceutical (01558) [3]